Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29205168 | 0.89 | MCHR1 (0.40) | TDP1ALDH1A1HSD11B1TP53 | |
| SCHEMBL29205160 | 0.87 | PROKR1 (0.34) | ALDH1A1SMN1; SMN2KMT2ATP53 | |
| SCHEMBL29205158 | 0.86 | ACKR3 (0.40) | HTTTDP1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27204453 | 0.85 | HSD11B1 (0.39) | LSSCYP2C19CYP2C9ALDH1A1HSD11B1 | |
| SCHEMBL27166114 | 0.85 | HSD11B1 (0.39) | LSSCYP2C19CYP2C9ALDH1A1HSD11B1 | |
| SCHEMBL27166076 | 0.83 | HSD11B1 (0.43) | ALDH1A1HSD11B1KMT2A | |
| SCHEMBL27166167 | 0.83 | HSD11B1 (0.39) | CYP2C19CYP2C9ALDH1A1HSD11B1LMNA | |
| SCHEMBL29205177 | 0.83 | HSD11B1 (0.39) | CYP2C19ALDH1A1HSD11B1LMNASMN1; SMN2 | |
| SCHEMBL29205132 | 0.82 | HSD11B1 (0.40) | CYP2C19HSD11B1 | |
| SCHEMBL30055420 | 0.82 | MGLL (0.40) | CYP2C19HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | LSS 181/4885HTT 4390/4885TDP1 3557/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | LSS 116/4885HTT 4409/4885TDP1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.